Cartesian Therapeutics Announces New Employment Inducement Grants
November 08 2024 - 7:05AM
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a
clinical-stage biotechnology company pioneering mRNA cell therapies
for the treatment of autoimmune diseases, today announced the
granting of inducement awards to two new employees. On November 4,
2024, the Company issued to these employees options to purchase an
aggregate of 4,854 shares of the Company’s common stock with an
exercise price of $19.11, the closing trading price of the
Company’s common stock on the Nasdaq Global Market on the date of
grant. The options were granted pursuant to the Company’s Amended
and Restated 2018 Employment Inducement Incentive Award Plan and
were approved by the Company’s board of directors. The option vests
as to 25% on November 4, 2025, and then in three equal annual
installments thereafter such that the options will be fully vested
on November 4, 2028. The options have a ten-year term. The options
were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as
an inducement material to the employees’ entry into employment with
the Company.
About Cartesian
Therapeutics
Cartesian Therapeutics is a clinical-stage
company pioneering mRNA cell therapies for the treatment of
autoimmune diseases. The Company’s lead asset, Descartes-08, is an
mRNA CAR-T in Phase 2b clinical development for patients with
generalized myasthenia gravis and Phase 2 development for systemic
lupus erythematosus, with a Phase 2 basket trial planned in
additional autoimmune indications. The Company’s clinical-stage
pipeline also includes Descartes-15, a next-generation, autologous
anti-BCMA mRNA CAR-T. For more information, please visit
www.cartesiantherapeutics.com or follow the Company on LinkedIn or
X, formerly known as Twitter.
Contact Information:Investor
Contact:Melissa ForstArgot Partnerscartesian@argotpartners.com
Media Contact:David RosenArgot
Partnersdavid.rosen@argotpartners.com
Cartesian Therapeutics (NASDAQ:RNAC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cartesian Therapeutics (NASDAQ:RNAC)
Historical Stock Chart
From Dec 2023 to Dec 2024